Company
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $CRL
Federal figures from USAspending, gathered Oct 25, 2026.
SEC revenue and federal obligations
- FY2026Oct 2025 to Sep 2026$62.6M$4.0B year to Dec 27, 2025
- FY2025Oct 2024 to Sep 2025$70.3M$4.0B year to Dec 28, 2024
- FY2024Oct 2023 to Sep 2024$64.8M$4.1B year to Dec 30, 2023
- FY2023Oct 2022 to Sep 2023$45.1MRevenue for this year not on file
- FY2022Oct 2021 to Sep 2022$61.1MRevenue for this year not on file
What these numbers are
Obligated means an agency committed the money to this company in that period (a signed contract action), as reported to USAspending. It is not a payment and not revenue: a contract can be funded for several years at once, and revenue is booked as the work is done. Some years can exceed revenue for that reason.
Prime contracts only, and only what is published. Work the company does as a subcontractor is not in these figures, and classified contracts are not published on USAspending at all. A low share can mean either. Contract values, ceilings and options are never added in.
Which units count: the USAspending recipient that is the company's SEC registrant; units of the company that USAspending's own records place under it (as parent, or in its family tree); and subsidiaries from the company's SEC Exhibit 21 that carry its name. Joint ventures, units now owned by someone else, and records that only share a name are held back. Both lists are below.
Earlier years count the units the company owns today. A unit we checked by hand (its USAspending parent is out of date) counts from the date the company bought it, or, where no filing gives that date, from the first date a filing shows the company owning it. Other units count for every year shown until their purchase dates are loaded.
Revenue bars are the company's own fiscal year from its 10-K, placed in the federal year it ends in; its fiscal year can end in a different month than the government's.
Fiscal year 2022 onward. Federal fiscal years run October to September; the company's own fiscal year may differ.
Units counted (7), held back (2)
- CHARLES RIVER LABORATORIES, INC.NAPSK1UAMAE5 · parent · Exhibit 21 subsidiary; USAspending files it under CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CHARLES RIVER LABORATORIES CELL SOLUTIONS, INC.NX7DKA7UH5M6 · parent · Exhibit 21 subsidiary; USAspending files it under CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CHARLES RIVER LABORATORIESSXYNSV89NBT1 · parent · Exhibit 21 subsidiary carrying the company's name
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.F2KENCWX3M63 · parent · the company's SEC name
- CHARLES RIVER LABORATORIES CLEVELAND, INC.U2K7J688V943 · parent · Exhibit 21 subsidiary; USAspending files it under CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITEDKWY4CPWDFNT6 · Exhibit 21 subsidiary; USAspending files it under CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CHARLES RIVER LABORATORIES, INC.GBNJK8JBCML5 · Exhibit 21 subsidiary; USAspending lists CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as its parent
Held back: a matching name we could not tie to this company firmly enough. A miss is better than a wrong link.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (its 12-month figure matches CHARLES RIVER LABORATORIES, INC.'s, so it likely rolls up that unit's money (counted once, through the unit))
- CHARLES RIVER LABORATORIES ASHLAND, LLC (its name includes another listed company's (ASH), so it may be shared)
Top agencies, contracts obligated in FY2026
- Department of Health and Human Services$62.2M
- Department of Veterans Affairs$353K
- Department of Defense$77K
Largest contracts active in the last 12 months
- Management, operation, professional, technical and support services for NIAID animal care facilities$95.8MNational Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Mar 13, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Aug 31, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Feb 28, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Sep 29, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Feb 28, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Sep 29, 2027
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Feb 28, 2026
- National Institutes of Health · CHARLES RIVER LABORATORIES, INC. · ends Sep 29, 2027
Amount: obligated to date on the contract, all years. Ranked by that amount among contracts with any action in the last 12 months. Counts only consolidated subsidiaries.
Lobbying
14 filings, 2023 to 2026. Paid lobbying firms $1.0M.
Firms: Bgr Government Affairs, Capitol Hill Consulting Group
Issues: Animals, Food Industry (safety, labeling, etc.), Health Issues, Pharmacy
Contacted: Senate, House Of Representatives, Health & Human Services, Dept Of (Hhs), Food & Drug Administration (Fda), State, Dept Of (Dos), Natl Institutes Of Health (Nih)
Revolving door: 7 lobbyists held government posts
- Christopher Davis Capitol Hill Consulting Group · last filed 2026Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011).
- Emily Elizabeth Wilkinson-Holland Capitol Hill Consulting Group · last filed 2026Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).
- Brian Sutter Capitol Hill Consulting Group · last filed 2026Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
- Kimberlee Trzeciak Capitol Hill Consulting Group · last filed 2026FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA
- John Stone Bgr Government Affairs · last filed 2025Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
- Maya Seiden Bgr Government Affairs · last filed 2025Intern, WH Counsels Office; Intern, Rep. Sam Gejdenson; Sp. Asst to Cab Sec., WH; Advisor to CoS, Energy Dept.; Sp Asst to Sec of Energy; Sen Advisor, Off of Dep. Sec of State; CoS Office of the Dep Sec of State for Management and Res.
- Remy Leigh Brim Mason Bgr Government Affairs · last filed 2025Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
Former posts as each lobbyist listed them ("covered position") on the company's Senate LDA filings.
From the company's Senate LDA filings. Firm fees and in-house spend are reported on different filings, so they are shown apart. Lobbying is legal and common; it shows what the company paid to be heard on, not what it got.
PAC giving
No corporate PAC tied to this company in the FEC records we hold.
Contracts ending in the next 18 months
- Management, operation, professional, technical and support services for NIAID animal care facilities$95.8MNational Institutes of Health · ends Mar 13, 2027 · options to Mar 13, 2029
- National Institutes of Health · ends Sep 29, 2027
- National Institutes of Health · ends Aug 31, 2027
Amount: obligated to date. From the contracts in HillSignal's records tied to this ticker; the full list of contracts ending across government is on Recompetes.
Insider trades
- Parisotto Shannon M CEVP, Disc & Safety AssessmentSold $1.3M · Oct 21, 2026
- Parisotto Shannon M CEVP, Disc & Safety AssessmentSold $507K · Oct 5, 2026
- Coleman Glenn EVP & Chief Financial OfficerBought $3K · Sep 30, 2026
- Foster James C DirectorSold $16.8M · Aug 25, 2026
- Parisotto Shannon M CEVP, Disc & Safety AssessmentSold $996K · Aug 19, 2026
- Andrews Nancy C DirectorSold $258K · Aug 18, 2026
Open-market buys and sells from SEC Form 4 filings; grants and option exercises left out, and trades whose filed price failed our market check. A 10b5-1 plan is a trading schedule set in advance, so those sells say little about the insider's view. The plan box is on filings from April 2023 on.